Sending report ...Contributors: View
Stephen R. Byrn
| Contributions | 3 (detailed usage) |
|---|---|
| Affiliation | Purdue University - West Lafayette |
| Web Site | http://www.ipph.purdue.edu/faculty/?uid=sbyrn |
| Biography | Dr. Stephen R. Byrn is the Charles B. Jordan Professor of Medicinal Chemistry in the School of Pharmacy at Purdue University in West Lafayette, Indiana. He is also Head of the Department of Industrial and Physical Pharmacy. Dr. Byrn received his B.A. degree in Chemistry from DePauw University and his Ph .D. degree in Chemistry from the University of Illinois, Urbana. He did postdoctoral research at UCLA. His research focuses on solid state chemistry, polymorphism, stability, manufacturing science, quality by design, and medicinal chemistry. Dr. Byrn opened up the field of solid state chemistry of drugs with his research and books of that title (first edition, 1982, second edition, 2000). Dr. Byrn has founded/cofounded and directed several programs at Purdue University including CAMP, the Center for AIDS Research, the Molecules to Market program, and Purdue’s graduate programs in regulatory and quality compliance. He is also one of the founders and a member of the executive committee of NIPTE (National Institute for Pharmaceutical Technology and Education). He continues to be involved in educating scientists in solid state chemistry, methods of analysis, and regulatory science. Dr. Byrn has served as chair of the Pharmaceutical Sciences Advisory Committee to the FDA and Chair of the Drug Substances Technical Committee, Product Quality Research Initiative. Dr. Byrn has extensive experience as a consultant in the pharmaceutical industry and currently serves as Purdue’s representative to the USP. Dr. Byrn is cofounder of SSCI, Inc. (Solid State Chemical Information) a cGMP research and information Company specializing in polymorphism, crystallization, analysis, problem solving and regulatory issues. SSCI, Inc. is now owned by Aptuit and Dr. Byrn serves as Head of the Aptuit Scientific Advisory Board. Dr. Byrn is also a technical founder of Andara now owned by Cyberkinetics, Inc. Andara specializes in devices and drugs for the treatment of spinal cord injury and CNS diseases. |
Contributions
-
Polymers for nanoparticle and nanocrystal formulations for drug delivery
- This resource has a 9.2 Ranking
-
Ranking is calculated from a formula comprised of user reviews and usage statistics. Learn more ›
Usage Stats Last 12 Months: updated 01 Nov, 2008 Users: 366 Reviews & Citations Google/IEEE Avg. Review: Citations: 0
366 users
15 May. 2007 | Online Presentations | Contributor(s): Stephen R. Byrn
Nanoparticles hold great promise for drug delivery applications. Nanoparticles might prove to be the only way to bring water insoluble, chemically unstable drugs to market. Because of this, this seminar will summarize the use of polymers to prepare and/or coat nanoparticles. Preliminary studies …
-
Quality by Design and Process Analytical Technology for Pharmaceutical Manufacturing in the 21st Century
- This resource has a 5.2 Ranking
-
Ranking is calculated from a formula comprised of user reviews and usage statistics. Learn more ›
Usage Stats Last 12 Months: updated 01 Nov, 2008 Users: 12 Reviews & Citations Google/IEEE Avg. Review: Citations: 0
12 users
21 Jul. 2008 | Online Presentations | Contributor(s): Stephen R. Byrn
PAT or Process Analytical Technology is an initiative and guidance from the U.S. FDA to encourage modernization of pharmaceutical manufacturing. In reality, PAT is a subset of the larger concept of Quality by Design which is the implementation of design concepts for pharmaceutical dosage forms and …
-
Strategies for Preparation and Manufacture of Polymer-based Nanoparticulate Formulations
- This resource has a 4.9 Ranking
-
Ranking is calculated from a formula comprised of user reviews and usage statistics. Learn more ›
Usage Stats Last 12 Months: updated 01 Nov, 2008 Users: 6 Reviews & Citations Google/IEEE Avg. Review: Citations: 0
6 users
21 Jul. 2008 | Online Presentations | Contributor(s): Stephen R. Byrn
Nanoparticles hold great promise for drug delivery applications. Several polymer-based formulations containing nanoparticles are in late phase development or on the market. In fact, polymer dispersions provide one of the best methods to prepare nanoparticles of small-molecule organic drugs. …